As of November 6, 2026, Kiora Pharmaceuticals Inc. is a publicly traded company (Nasdaq: KPRX); its largest reported holder is Nantahala Capital, with 9.99% on Schedule 13G/A of August 14, 2026, then Perceptive Advisors (9.99%). The largest insider holding is Brian Strem, the chief executive and president, with 58,823 shares (1.3% of shares outstanding), per Form 4 of July 2, 2026 (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Kiora Pharmaceuticals Inc.? See the free Snapshot first.
Free to see. No signup.
Is Kiora Pharmaceuticals Inc. a real, registered company?
- Kiora Pharmaceuticals, Inc. files with the SEC under CIK 1372514 (its SEC filings).
- Its shares are listed under the ticker KPRX on Nasdaq (also KPHMW) (SEC company record).
- Incorporated in Delaware; business address in Encinitas, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under KIORA PHARMACEUTICALS INC in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Keith Lane, Executive Vice President, Head (Form 8-K filed 2026-09-08). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Baselake Partners, LP (filed 2026-09-17).
Who are Kiora Pharmaceuticals Inc.'s owners and officers?
Kiora Pharmaceuticals Inc.: incorporated in Delaware; business address in Encinitas, California; industry Pharmaceutical Preparations (Schedule 13G, 2026-09-17).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer (Form D, 2026-04-21)
- : Executive Officer (Form D, 2026-04-21)
- : Director (Form D, 2026-04-21)
- : Director (Form D, 2026-04-21)
- : Director (Form D, 2026-04-21)
- : Director (Form D, 2026-04-21)
- : Director (Form D, 2026-04-21)
- : Director (Form D, 2026-04-21)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-09-17 | Baselake Partners, LP | 5.8% |
| Schedule 13G/A, 2026-08-14 | Nantahala Capital Management, LLC | 9.99% |
| Schedule 13G/A, 2026-08-14 | Adar1 Capital Management, LLC | 9.9% |
| Schedule 13G, 2026-08-10 | Perceptive Advisors LLC | 9.99% |
| Schedule 13G, 2026-05-15 | Alyeska Investment Group, L.P. | 9.99% |
| Schedule 13G/A, 2026-05-15 | Nantahala Capital Management, LLC | 9.99% |
| Schedule 13G/A, 2026-05-15 | Nantahala Capital Partners Limited Partnership | 3.39% |
| Schedule 13G/A, 2026-02-11 | Rosalind Advisors, Inc. | 9.9% |
| Schedule 13G/A, 2026-01-29 | Orin Hirschman | 4.9% |
| Schedule 13G/A, 2025-11-14 | Nantahala Capital Management, LLC | 9.99% |
| Schedule 13G, 2025-08-14 | Nantahala Capital Partners Limited Partnership | 5.3% |
| Schedule 13G/A, 2025-08-14 | Adar1 Capital Management, LLC | 9.9% |
Questions about who owns Kiora Pharmaceuticals Inc.
Who owns Kiora Pharmaceuticals Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Kiora Pharmaceuticals Inc.: Nantahala Capital Management, LLC (9.99%, Schedule 13G/A, filed 2026-08-14), Perceptive Advisors LLC (9.99%, Schedule 13G, filed 2026-08-10), Alyeska Investment Group, L.P. (9.99%, Schedule 13G, filed 2026-05-15), Adar1 Capital Management, LLC (9.9%, Schedule 13G/A, filed 2026-08-14) and Rosalind Advisors, Inc. (9.9%, Schedule 13G/A, filed 2026-02-11); 1 more is listed above.
Who are the largest shareholders of Kiora Pharmaceuticals Inc.?
By the share each holder's latest filing reports, the largest holders of Kiora Pharmaceuticals Inc. on this page are Nantahala Capital Management, LLC (9.99%), Perceptive Advisors LLC (9.99%) and Alyeska Investment Group, L.P. (9.99%).
When did Nantahala Capital Management, LLC buy into Kiora Pharmaceuticals Inc.?
The filings give report dates, not purchase dates. The earliest filing from Nantahala Capital Management, LLC on this page is the Schedule 13G/A, filed 2025-11-14, reporting 9.99%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Kiora Pharmaceuticals Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Kiora Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kiora Pharmaceuticals Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
21 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-09-08 | Keith Lane | Executive Vice President, Head | appointed |
Which insiders own Kiora Pharmaceuticals Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 58,823 shares (1.3% of shares outstanding) (Form 4, 2026-07-02).
- , the chief development officer: 31,741 shares (0.72% of shares outstanding) (Form 4, 2026-04-02).
- , the chief financial officer: 26,064 shares (0.59% of shares outstanding) (Form 4, 2026-07-02).
Shares outstanding: 4,424,387 as of 2026-08-05, from the company's latest SEC cover page.
How much has Kiora Pharmaceuticals Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-04-21 | $5M | $5M |
| Form D, 2024-02-14 | $15M | $15M |
| Form D, 2023-02-17 | $0 | $10M |
| Form D, 2023-02-17 | $200K | $200K |
Keep reading
More on Kiora Pharmaceuticals Inc. and the records around it.
Kiora Pharmaceuticals Inc. elsewhere on the record
- 5%+ stake filings Sep 2026
- Leadership changes Sep 2026
- Company profile and every filing Apr 2026
- Form D filing Apr 2026
Companies that share a holder
- NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP also filed stake reports on 6 other companies: FEMASYS INC. (Aug 2026), AZITRA, INC. (Aug 2026), ABEONA THERAPEUTICS INC. (May 2026)
- Baselake Partners, LP also filed stake reports on 7 other companies: Passage Bio, Inc. (Jun 2026), Generation Bio Co. (Feb 2026), Athira Pharma, Inc. (Feb 2026)
- Rosalind Advisors, Inc. also filed stake reports on 11 other companies: DELCATH SYSTEMS, INC. (Oct 2026), FEMASYS INC (Aug 2026), FENNEC PHARMACEUTICALS INC. (Aug 2026)
Related pages
Funding and filing historyLeadership changes5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/kiora-pharmaceuticals-inc